WuXi Biologics WKN: A2QJCN ISIN: KYG970081173 Forum: Aktien User: Summer.76

POSITIVE PROFIT ALERT Download https://doc.irasia.com/listco/hk/wuxibiologics/announcement/a230213.pdf

DATE OF BOARD MEETING Download https://doc.irasia.com/listco/hk/wuxibiologics/announcement/a230213a.pdf

"Profit Forecast" WuXi Biologics (02269 HK) Estimates Annual Earnings 30% More, Revenue Increases 48% http://www.aastocks.com/tc/stocks/news/aafn-news/NOW.1244741/1

http://www.aastocks.com/en/stocks/news/aafn-con/now.1244673/latest-news

https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/does-wuxi-biologics-cayman-hkg2269-deserve-a-spot-on-your-wa/amp

https://www.marketscreener.com/amp/quote/stock/WUXI-BIOLOGICS-CAYMAN-I-37230806/news/WuXi-Biologics-Receives-the-Asset-ESG-Corporate-Platinum-Award-for-Second-Consecutive-Year-42955659/

10 minutes with Shauna McCabe- WuXi Biologics https://www.breakingnews.ie/amp/advertising-feature/10-minutes-with-shauna-mccabe-wuxi-biologics-1430970.html

http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1242734/popular-news/HK6

http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1242682/company-news/HK6

WuXi Biologics erweitert Standort https://www.wuppertal.de/presse/meldungen/meldungen-2023/januar/wuxi.php

WuXi Bio ist die Tochter der AppTec und das Portfolio lässt sich am besten auf deren Seiten herauslesen. Wäre daher nicht gerecht, die AppTec eher dem chemisch-pharmazeutischen Bereich zuzuordnen und die Bio auf die End-to-end Lösungen zu reduzieren.

Was ist der Unterschied zwischen WuXi Biologic und Wuxi Apptac ?

https://e-fundresearch.com/newscenter/167-comgest/artikel/46581-comgest-fondsmanager-chen-gelingt-china-im-jahr-des-hasen-das-comeback

Bank of America Securities Upgrades WuXi Biologics (02269 HK) to "Buy" and Raises Target Price to $114.6 http://www.aastocks.com/tc/stocks/news/aafn-con/now.1239489/latest-news

https://www.wuppertal.de/presse/meldungen/meldungen-2023/januar/102010100000464653.php

...After the completion, WuXi Biologics Holdings' shareholding will be reduced from about 15.14% to 13.82%, and it will continue to be the company's major shareholder. Allotment shareholders promise a 3-month lock-up period. Li Ge, chairman and non-executive director of the group, has about 19.66% of the control over WuXi Biologics Holdings and 55.03% of the votes at the general meeting of shareholders. WuXi Biologics Holdings holds about 640 million shares of WuXi Biologics, accounting for about 15.14% of the total issued share capital of the company.